文献速递临床试验与 GCP医学教育与科研方法

中医治疗高血压性脑出血临床试验核心结局指标集的构建:一项研究方案

Development of a core outcome set for hypertensive intracerebral hemorrhage in clinical trials of traditional Chinese medicine: a study protocol.
PubMed 文献 · Trials · 2022-10-12

本研究方案旨在为中医治疗高血压性脑出血的临床试验建立核心结局指标集(COS)。方法包括系统文献综述和半结构化访谈形成结局清单,邀请医护人员和患者参与两轮德尔菲调查,最终通过面对面共识会议确定应测量哪些结局及测量时机与方法。预期可提高结局报告一致性、减少报告偏倚,促进研究数据在Meta分析中的再利用。

要点

  • 中医治疗高血压性脑出血的随机对照试验存在结局异质、测量时点不统一等问题。
  • 拟通过系统文献综述、半结构化访谈、两轮德尔菲调查和共识会议构建核心结局指标集。
  • 核心结局指标集将包括中医核心证候,并明确结局测量内容、时机与方法。

核心结论

  • 通过构建包含中医核心证候的高血压性脑出血核心结局指标集,可提高结局报告一致性、减少报告偏倚,促进研究数据在Meta分析中的再利用并为医疗决策提供依据。

研究设计与样本

  • 研究方案:先通过系统文献综述和半结构化访谈形成结局清单,再邀请医护人员和高血压性脑出血患者参与两轮德尔菲调查,最后召开面对面共识会议确定核心结局指标集。
  • 本研究已在Core Outcome Measures in Effectiveness Trials数据库注册,注册号为1475,注册时间为2019年12月。

主要发现

  • 在中国,高血压性脑出血占所有原发性脑出血病例的75%。
  • 中医治疗高血压性脑出血的随机对照试验存在结局异质、测量时点不统一等问题,导致系统综述/Meta分析仅能纳入少量研究。
  • 既往结局指标未考虑患者及其他利益相关者的意愿。

关键数值与推荐

  • 核心结局指标集将明确应测量哪些结局以及何时、如何测量这些结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intracerebral hemorrhage (ICH) is a devastating disease, its mortality and disability rate are high. In China, hypertensive intracerebral hemorrhage (HICH) is responsible for 75% of all the cases of primary ICH. A lot of randomized controlled trials (RCTs) of traditional Chinese medicine (TCM) for treating HICH have been carried out. However, these RCTs have a lot of problems, such as heterogeneous outcomes, non-uniform point of measurement. These lead to systematic review/meta-analysis only can include a small number of studies. And outcome measures did not take the wishes of patients and other stakeholders into account. The aim of this study is to establish the core outcome set (COS) for future TCM clinical trials of HICH. METHODS AND ANALYSIS: First, we will develop a long list of general outcomes by making systematic literature review and semi-structured interviews. Then healthcare professionals and patients with HICH will be invited to participate in two rounds of the Delphi survey to determine the importance of the outcome. Finally, a face-to-face consensus meeting will be conducted to determine the final COS of HICH, including what outcomes should be measured and when and how to measure the outcomes. RESULTS: We aim to develop a COS that includes TCM core syndrome for HICH to determine what outcomes should be reported and when and how to measure them. CONCLUSION: By doing this, we can increase the reporting consistency and reduce the reporting bias in the outcome, which leads to the reuse of research data in meta-analysis and the making of informed healthcare decisions. ETHICS AND DISSEMINATION: The entire project has received approval from the Ethics Committee of Xiyuan Hospital, China Academy of Chinese Medical Sciences. The final COS will be published and reported at the national and international conferences. TRIAL REGISTRATION: This study is registered with the Core Outcome Measures in Effectiveness Trials database as study 1475 . Registered on December 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jia M, Lu Y, Liang X, et al. Development of a core outcome set for hypertensive intracerebral hemorrhage in clinical trials of traditional Chinese medicine: a study protocol. Trials. 2022. PMID: 36224599. doi:10.1186/s13063-022-06801-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。